Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Sep;73(9):1768-1769.
doi: 10.1002/art.41806. Epub 2021 Jul 29.

Use of Tofacitinib in the Context of COVID-19 Vaccination: Comment on the American College of Rheumatology Clinical Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases

Mahta Mortezavi  1 , Sujatha Menon  1 , Kristen Lee  2 , Jose Rivas  3
Affiliations
Comment

Use of Tofacitinib in the Context of COVID-19 Vaccination: Comment on the American College of Rheumatology Clinical Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases

Mahta Mortezavi et al. Arthritis Rheumatol. 2021 Sep.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Least squares (LS) mean changes from baseline in C‐reactive protein (CRP) levels (A), Disease Activity Score in 28 joints (4‐variable) using the erythrocyte sedimentation rate (DAS28‐4[ESR]) (B), and Clinical Disease Activity Index (CDAI) (C) over time during the sub‐study of the long‐term extension study, ORAL Sequel. Shaded areas indicate the dose‐interruption period. Baseline was defined as visit 1 of the sub‐study. aLS mean change (Δ) in continuous treatment group minus LS mean change in interrupted treatment group. bid = twice a day; 95% CI = 95% confidence interval. ** = P < 0.001; *** = P < 0.0001 for interrupted versus continuous treatment. Adapted from Figure 3 in Kaine et al (5) (available at https://link.springer.com/article/10.1007%2Fs10067-020-04956-1) by removing the original panel B from the figure; used under Creative Commons attribution 4.0 International (CC BY 4.0) at https://creativecommons.org/licenses/by/4.0/.
See this image and copyright information in PMC

Comment in

  • Reply.
    Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Gravallese EM, Bass AR, Calabrese C, Harpaz R, Kroger A, Sadun RE, Turner AS, Williams EA, Mikuls TR. Curtis JR, et al. Arthritis Rheumatol. 2021 Sep;73(9):1769-1770. doi: 10.1002/art.41805. Epub 2021 Jul 16. Arthritis Rheumatol. 2021. PMID: 34042308 Free PMC article. No abstract available.

Comment on

References

    1. Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 1. Arthritis Rheumatol 2021;73:1093–107. - PMC - PubMed
    1. Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME, et al. The mechanism of action of tofacitinib: an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2016;34:318–28. - PubMed
    1. Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis 2016;75:687–95. - PMC - PubMed
    1. Winthrop KL, Korman N, Abramovits W, Rottinghaus ST, Tan H, Gardner A, et al. T cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment. J Am Acad Dermatol 2017;78:1149–55.e1. - PubMed
    1. Kaine J, Tesser J, Takiya L, DeMasi R, Wang L, Snyder M, et al. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis. Clin Rheumatol 2020;39:2127–37. - PMC - PubMed

Grants and funding